Follow up on Purdue's approval of Hysingla - Relmada Therapeutics

Print E-mail
Thursday, 20 November 2014 20:19

New York-based Relmada Therapeutics (RLMD) has reinvented four proven and promising drug candidates with novel delivery systems to create new drugs for new indications.

Read more...
 

RELMADA THERAPEUTICS APPOINTS MICHAEL BECKER AS SENIOR VICE PRESIDENT OF FINANCE AND CORPORATE DEVELOPMENT

Print E-mail
Tuesday, 04 November 2014 19:51

New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.

Read more...
 

LA BioMed Receives Phase II Grand Challenges Explorations Funding

Print E-mail
Monday, 03 November 2014 20:41

LOS ANGELES - Los Angeles Biomedical Research Institute ( LA BioMed) announced today that it will receive Phase II funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables individuals worldwide to test bold ideas to address persistent health and development challenges.

Read more...
 

Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases

Print E-mail
Monday, 27 October 2014 15:59

HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, announced today that researchers at Case Western Reserve University will conduct a preclinical study of the Company's PLacental eXpanded (PLX)-RAD cells.

Read more...
 

Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program

Print E-mail
Monday, 27 October 2014 15:23

 

New York, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, and Albert Einstein College of Medicine of Yeshiva University, a research-intensive medical school in Bronx, NY, started development of an antibody construct labeled with actinium 225 using a novel technology that potentially allows for the expansion of use of the Company’s proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates.
Read more...
 

TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease

Print E-mail
Wednesday, 22 October 2014 22:39
SEATTLE, WASHINGTON--TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM  vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.
Read more...
 

PROVECTUS’ INTRALESIONAL PV-10 CLINICAL DATA TO BE PRESENTED TO THE 2014 INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH

Print E-mail
Thursday, 16 October 2014 18:07
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.
Read more...
 

RELMADA THERAPEUTICS REINFORCES BALANCE SHEET WITH $15.2 MILLION FROM EXERCISE OF WARRANTS

Print E-mail
Thursday, 16 October 2014 18:04

New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014.

Read more...
 

INC RESEARCH SIGNS AGREEMENT TO PERFORM FDA DUE DILIGENCE AUDIT OF REGULATORY DOCUMENTS FOR PROVECTUS BIOPHARMACEUTICALS

Print E-mail
Tuesday, 14 October 2014 13:57

KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.

Read more...
 

Pluristem Wins Cell Therapy Patent Case in Europe; European Patent Office Confirms Validity of Amended Claims

Print E-mail
Tuesday, 07 October 2014 10:23
Read more...
 
<< Start < Prev 1 3 > End >>

Page 1 of 3

Newsletter

BioMedReports This is how a living, beating heart is grown from stem cells. http://t.co/MLrFZyj3la
8hreplyretweetfavorite
BioMedReports FDA Orders New Label For Biogen Idec's MS Drug; Exact Sciences Announces Final Payment Decision for Cologuard®... http://t.co/LwIBwixMkt
9hreplyretweetfavorite
BioMedReports OncoMed Offers Data from Demcizumab; Celgene Receives Positive CHMP Opinion For OTEZLA: Below is a look at som... http://t.co/ZkvEC7x99Y
Benzinga.com supporter Seeking Alpha Certified